摘要
目的:探讨MIC-1作为新的肿瘤标志物在胰腺癌临床血清学诊断中的应用价值.方法:采用酶联免疫方法检测101例胰腺癌、10例胰腺良性病变患者及50例正常人血清中的MIC-1表达水平,并与肿瘤标记物CA199进行比较.结果:胰腺癌患者血清中MIC-1表达水平(1427±1056 ng/L)显著高于胰腺良性肿瘤(362±177 ng/L)和正常人血清水平(299±159 ng/L)(P<0.001).MIC-1检测胰腺癌的敏感性、特异性、阳性预测值、阴性预测值和AUC分别为81.2%、94%、96.5%、71.2%和0.92.分别高于CA199的相应对应值72.4%、89.6%、93.4%、61.4%和0.86.与CA199联合检测时,敏感性可提高至91.1%.结论:MIC-1有可能成为用于胰腺癌临床诊断的新肿瘤标记物.
AIM： To evaluate the value of serum macrophage inhibitory cytokine-1 （MIC-1） as a novel marker for diagnosing pancreatic cancer. METHODS： Serum MIC-1 levels were measured by sandwich ELISA assay in 101 patients with pancreatic adenocarcinomas, 10 patients with benign pancreatic tumors, and 50 healthy control subjects. The diagnostic performance of se-rum MIC-1 as a marker of pancreatic cancer was compared with that of serum CA199. RESULTS： MIC-1 levels were significantly higher in patients with pancreatic adenocarcinoma than in those with benign pancreatic neoplasms or in healthy controls （1427±1056 ng/L vs 362±177 ng/L, 299±159 ng/L）. The diagnostic accuracy of MIC-1 （sensitivity 81.2%, specificity 94%, positive predictive value 96.5%, negative predic- tive value 71.2%; AUC 0.92） at detecting pancreatic adenocarcinomas was higher than that of CA199 （sensitivity, 72.4% specificity 89.6%, positive predictive value 93.4%, negative predictive value 61.4%; AUC 0.86）, and the combination of MIC-1 and CA199 significantly improved diagnostic sensitivity （91.1 %）. CONCLUSION： MIC-1 mor marker and aid in atic adenocarcinoma.
出处
《世界华人消化杂志》
CAS
北大核心
2007年第34期3644-3648,共5页
World Chinese Journal of Digestology
基金
国家十五攻关资助项目
No.2004BA703B11
国家高技术研究发展计划(863计划)资助项目
No.2007AA02Z485~~
关键词
胰腺癌
巨噬细胞抑制因子
CA199
酶联免疫方法
Pancreatic adenocarcinomas
Macro-phage inhibitory cytokine-1
CA199
Enzyme linkedimmunosorbent assay
